Aprepitant Can Be Given, But Requires Tacrolimus Dose Reduction and Close Monitoring
Yes, aprepitant (Emend) can be safely administered to a stable liver transplant recipient on tacrolimus or cyclosporine with mildly elevated liver enzymes, but you must reduce the tacrolimus dose and monitor levels closely due to significant drug-drug interactions.
Key Drug Interaction Concern
Aprepitant is a moderate CYP3A4 inhibitor 1. Since tacrolimus is metabolized via CYP3A4, aprepitant will increase tacrolimus concentrations significantly. The FDA label explicitly documents that aprepitant increases midazolam (another CYP3A4 substrate) AUC by 2.3-fold on Day 1 and 3.3-fold on Day 5 1. Expect similar magnitude effects on tacrolimus.
Clinical Evidence in Transplant Patients
Research specifically examining this interaction in hematopoietic stem cell transplant patients found that aprepitant increased dose-corrected tacrolimus concentrations from 8.12 ng/mL/mg pre-aprepitant to 11.63 ng/mL/mg during aprepitant therapy (P<0.01) 2. While the authors concluded this was "not clinically significant," this represents a 43% increase in tacrolimus exposure that absolutely requires dose adjustment in clinical practice.
Practical Management Algorithm
Before starting aprepitant:
- Obtain baseline tacrolimus trough level
- Reduce tacrolimus dose by 30-50% when initiating aprepitant
During aprepitant therapy (Days 1-3):
- Monitor tacrolimus trough levels daily if possible, at minimum every 2-3 days
- Target therapeutic range: 5-15 ng/mL (adjust based on time post-transplant)
- Adjust tacrolimus doses based on levels, not on fixed schedule
After aprepitant discontinuation:
- Continue monitoring tacrolimus levels for 7-10 days
- The interaction persists beyond 48 hours post-discontinuation 2
- Gradually increase tacrolimus back toward baseline dose as levels decline
Hepatic Impairment Considerations
The FDA label indicates that in patients with moderate hepatic impairment (Child-Pugh 7-9), aprepitant AUC increased by only 10-18%, which is not clinically meaningful 1. For mild hepatic impairment (Child-Pugh 5-6), aprepitant AUC actually decreased. Therefore, mildly elevated liver enzymes in a stable transplant recipient should not preclude aprepitant use—the primary concern remains the tacrolimus interaction, not aprepitant metabolism.
Antiemetic Efficacy Evidence
Aprepitant is strongly recommended for highly emetogenic chemotherapy. Guidelines support a three-drug combination of NK₁ receptor antagonist (aprepitant), 5-HT₃ antagonist, and dexamethasone for high-dose chemotherapy, including in transplant conditioning regimens 3. Multiple trials demonstrated significantly reduced vomiting (complete response rates 58% vs 41%, P=0.004) with acceptable safety profiles 3.
Critical Pitfalls to Avoid
- Do not use standard tacrolimus dosing during aprepitant therapy—this will cause supratherapeutic levels and potential toxicity
- Do not assume the interaction resolves immediately after stopping aprepitant—continue monitoring for at least one week
- Watch for tacrolimus toxicity signs: nephrotoxicity (rising creatinine), neurotoxicity (tremor, headache, confusion), or hyperkalemia
- Consider the dexamethasone interaction as well: aprepitant increases dexamethasone AUC by 2.2-fold 1, so reduce dexamethasone doses by approximately 50% when used in the antiemetic regimen
Alternative Consideration
If cyclosporine is the immunosuppressant instead of tacrolimus, the same CYP3A4 interaction principles apply—reduce cyclosporine dose and monitor levels closely.
The bottom line: Aprepitant is not contraindicated, but requires proactive dose management of tacrolimus with intensive therapeutic drug monitoring to prevent toxicity while maintaining adequate immunosuppression.